Tumor lysis, adverse events, and dose adjustments in 297 venetoclax treated CLL in routine clinical practice

PURPOSE: Clinical trials of venetoclax reported negligible rates of clinical tumor lysis syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL) when using an extended dose escalation schedule. We aimed to understand TLS prophylaxis, rates of select adverse events (AEs), and impact of dos...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Clin Cancer Res
Main Authors: Roeker, Lindsey E., Fox, Christopher P., Eyre, Toby A., Brander, Danielle M., Allan, John N., Schuster, Stephen J., Nabhan, Chadi, Hill, Brian T., Shah, Nirav N., Lansigan, Frederick, Yazdy, Maryam, Cheson, Bruce D., Lamanna, Nicole, Singavi, Arun K., Coombs, Catherine C., Barr, Paul M., Skarbnik, Alan P., Shadman, Mazyar, Ujjani, Chaitra S., Tuncer, Hande H., Winter, Allison M., Rhodes, Joanna, Dorsey, Colleen, Morse, Hannah, Kabel, Charlene, Pagel, John M., Williams, Annalynn M., Jacobs, Ryan, Goy, Andre, Muralikrishnan, Sivraj, Pearson, Laurie, Sitlinger, Andrea, Bailey, Neil, Schuh, Anna, Kirkwood, Amy A., Mato, Anthony R.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2019
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC8020996/
https://ncbi.nlm.nih.gov/pubmed/31004001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-0361
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים